{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SB-485232", "query": { "intervention": "SB-485232" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SB-485232&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T10:29:51.976Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00085904", "title": "Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor Cancer", "Lymphoma" ], "interventions": [ { "name": "SB-485232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2004-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-10-13", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 3, "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • Pittsburgh, Pennsylvania", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085904" }, { "nct_id": "NCT01768338", "title": "Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Ofatumumab combined with SB-485232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael John Robertson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2013-02", "completion_date": "2017-08-03", "has_results": false, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768338" }, { "nct_id": "NCT00107718", "title": "Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "SB-485232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2004-11-15", "completion_date": "2006-05-19", "has_results": false, "last_update_posted_date": "2017-07-27", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107718" }, { "nct_id": "NCT05306080", "title": "Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "CRS - Cytokine Release Syndrome", "HLH" ], "interventions": [ { "name": "Tadekinig alfa (IL-18BP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-04-17", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05306080" }, { "nct_id": "NCT00500058", "title": "A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "SB-485232", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2007-07-31", "completion_date": "2010-03-04", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 2, "location_summary": "Chicago, Illinois • Indianapolis, Indiana", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00500058" }, { "nct_id": "NCT04787042", "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Carcinoma", "MSI-High" ], "interventions": [ { "name": "ST-067", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Simcha IL-18, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2021-08-06", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04787042" }, { "nct_id": "NCT06588660", "title": "ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Vevoctadekin", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-12-18", "completion_date": "2025-02-14", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06588660" }, { "nct_id": "NCT00085878", "title": "Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor Cancer" ], "interventions": [ { "name": "SB-485232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2003-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-10-16", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 4, "location_summary": "Santa Monica, California • Indianapolis, Indiana • Durham, North Carolina + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085878" }, { "nct_id": "NCT02277392", "title": "A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian, Fallopian Tube and Peritoneal Cancer" ], "interventions": [ { "name": "Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells", "type": "BIOLOGICAL" }, { "name": "SB---485232 (Human recombinant Interleukin---18)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2014-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-09-27", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277392" }, { "nct_id": "NCT03113760", "title": "Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NLRC4-MAS", "XIAP Deficiency" ], "interventions": [ { "name": "Tadekinig alfa", "type": "DRUG" }, { "name": "0.9% sodium chloride", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AB2 Bio Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2017-07-21", "completion_date": "2023-11-02", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-04T10:29:51.976Z", "location_count": 6, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113760" } ] }